The Therapeutic Potential of Neuropeptide Y

Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659–60 Potter EK. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther 1988; 37: 251–73 Grundemar L, Hakanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci 1994; 15: 153–9 Colmers WF, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurones. Trends Neurosci 1994; 17: 373–9 Wettstein JG, Earley B, Junien JL. Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 1995; 65: 397–414 Gehlert DR. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci 1994; 55: 551–62 Allen CJ, Koenig JI. Central and peripheral significance of neuropeptide Y and its related peptides. Ann NY Acad Sci 1990; 611. Wahlestedt C, Reis DJ. Neuropetide Y-related peptides and their receptors — are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol 1993; 32: 309–52 Herzog H, Hort YJ, Ball HJ, et al. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 1992; 89: 5794–8 Larhammar D, Blomqvist AG, Yee F, et al. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 1992; 267: 10935–8 Rose PM, Fernandes P, Lynch J, et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem 1995; 270: 22661–4 Rimland J, Xin W, Sweetnam P, et al. Sequence and expression of a neuropeptide Y receptor cDNA. Mol Pharmacol 1991; 40: 869–75 Jazin EE, Yoo H, Blomqvist AG, et al. A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. Regul Pept 1993; 47: 247–58 Bard JA, Walker MW, Branchek TA, et al. Cloning and characterisation of a novel human neuropeptide Y/ peptide YY/pan-creatic peptide receptor subtype (Y4) [abstract]. Soc Neurosci 1995; 21: 1012 Matthews JE, Jansen M, Slepetis RJ, et al. Novel high affinity NPY antagonist identifies different subclasses of Y2 type of NPY receptors [abstract]. Soc Neurosci 1995; 21: 1593 Fuxe K, Agnati LF, Harfstrand A, et al. On the role of neuropeptide Y in information handling in the central nervous system in normal and physiopathological states. Focus on volume transmission and neuropeptide Y/alpha2 receptor interactions. Ann N Y Acad Sci 1990; 579: 28–67 Tabarin A, Cassiede P, Minot AP, et al. Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities. Acta Endocrinol 1993; 128: 243–50 Michel MC, Buschauer A. Neuropeptide Y and its antagonists. Drugs Future 1992; 17: 39–45 WestlindDanielsson A, Unden A, Abens J, et al. Neuropeptide Y receptors and the inhibition of adenylate cyclase in the human frontal and temporal cortex. Neurosci Lett 1987; 74: 237–42 Aakerlund L, Gether U, Fuhlendorff J, et al. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Letters 1990; 260: 73–8 Wiley JW, Gross RA, Macdonald RL. Agonists for neuropeptide Y receptor subtypes NPY-1 and NPY-2 have opposite actions on rat nodose neuron calcium currents. J Neurophysiol 1993; 70: 324–30 Kar S, Quiron R. Quantative autoradiographic localization of [125I] neuropeptide Y binding sites in the rat spinal cord and the effects of neonatal capsaicin, dorsal rhizotomy and peripheral axotomy. Brain Res 1992; 574: 333–7 Mantyh PW, Allen CJ, Rogers S, et al. Some sensory neurones express neuropeptide Y receptors: potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injury. J Neurosci 1994; 14: 3958–68 Walker MW, Ewald DA, Perney TM, et al. Neuropeptide Y-like modulates neurotransmitter release and Ca2+ currents in rat sensory neurons. J Neurosci 1988; 8: 2438–46 Hirning LD, Fox AP, Miller RJ. Inhibition of calcium currents in cultured myenteric neurons by neuropeptide Y: evidence for direct receptor/channel coupling. Brain Res 1990; 532: 120–30 Ewald DA, Matthies HJG, Perney TM, et al. The effect of down regulation of protein kinase C on the inhibitory modulation of dorsal root ganglion neuron Ca2+ currents by neuropeptide Y. J Neurosci 1988; 8: 2447–51 Zhang X, Bao L, Xu ZQ, et al. Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons. Proc Natl Acad Sci USA 1994; 91: 11738–42 Vaysse PJ-J, Walker MW, Gerald C, et al. NPY, PYY or PP alter cAMP and Ca++ in cells expressing cloned human Y2 or Y4 receptors [abstract]. Soc Neurosci 1995; 21: 1596 Brown BJ. Neuronal localisation of neuropeptide Y gene expression in the rat brain. J Comp Neurol 1989; 290: 358–68 Dawbarn D, Hunt SP, Emson PC. Neuropeptide Y: regional distribution, chromatographic characterization and immunohistochemical demonstration in post-mortem human brain. Brain Res 1984; 296: 168–73 Hunt SP, Emson PC, Gilbert R, et al. Presence of avian pancreatic polypeptide-like immunoreactivity in catecholamine and methionine-enkephalin-containing neurones within the central nervous system. Neurosci Lett 1981; 21: 125–30 Allen JM, Gibson SJ, Adrian TE, et al. Neuropeptide Y in human spinal cord. Brain Res 1984; 308: 145–8 Gray TS, Morley JE. Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous system. Life Sci 1986; 38: 389–401 Lundberg JM, Franco Cereceda A, Lacroix JS, et al. Neuropeptide Y and sympathetic neurotransmission. Ann NY Acad Sci 1990; 611: 166–74 Pernow J, Schwieler J, Kahan T, et al. Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am J Physiol Heart Circ Physiol 1989; 257: H866–72 Haass M, Cheng B, Richardt G, et al. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 71–8 Pernow J, Lundberg JM. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha2, NPY and angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 379–85 Martire M, Pistritto G, Mores N, et al. Presynaptic α2-adreno-ceptors and neuropeptide Y Y2 receptors inhibit [3H]noradrenaline release from rat hypothalamic synaptosomes via different mechanisms. Neurosci Lett 1995; 188: 9–12 Gibson SJ, Polak JM, Allen JM, et al. The distribution and origin of a novel brain peptide, neuropeptide Y in the spinal cord of several mammals. J Comp Neurol 1984; 227: 78–91 Ghilardi JR, Allen CJ, Vigna SR, et al. Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons. Brain Res 1994; 633: 33–40 Doyle CA, Maxwell DJ. Direct catecholaminergic innervation of the spinal dorsal horn with axons ascending in the dorsal columns in the cat. J Comp Neurol 1993; 331: 434–44 Doyle CA, Maxwell DJ. Neuropeptide Y-immunoreactive terminals form axo-axonic synatic arrangements in the substantia gelatinosa (lamina II) of the cat spinaldorsal horn. Brain Res 1993; 603: 157–61 Doyle CA, Maxwell DJ. Light and electron-microscopic analysis of neuropeptide Y immunoreactive profiles in the cat spinal dorsal horn. Neuroscience 1994; 61: 107–21 Rowan S, Todd AJ, Spike RC. Evidence that neuropeptide Y is present in GABAergic neurons in the superficial dorsal horn of the rat spinal cord. Neuroscience 1993; 53: 537–45 Castro-Lopes JM, Tavaras I, Tolle TR, et al. Increase in GABAergic cells and GABA levels in the spinal cord in unilateral inflammation in the hind limb in the rat. Eur J Neurosci 1992; 4: 296–301 Barber RP, Vaughn JE, Saito K, et al. GABAergic terminals are presynaptic to primary afferent terminals in the substantia gelatinosa of the rat spinal cord. Brain Res 1978; 141: 35–55 Sheikh SP, Holst JJ, SkakNielsen T, et al. Release of NPY in pig pancreas: Dual parasympathetic and sympathetic regulation. Am J Physiol Gastrointest Liver Physiol 1988; 255: G46–54 Dumont Y, Fournier A, StPierre S, et al. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 1993; 13: 73–86 Michel MC, Leweljohann K, Farke W, et al. Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. Am J Physiol Regul Integr Comp Physiol 1995; 268: R192–200 Dumont Y, Fournier A, StPierre S, et al. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using (125I)(Leu31, Pro34)peptide YY and (125I)peptide YY3-36 as selective Y1 and Y2 radioligands. J Pharmacol Exp Ther 1995; 272: 673–80 Illes P, Finta EP, Nieber K. Neuropeptide Y potentiates via Y2-receptors the inhibitory effect of noradrenaline in rat locus coeruleus neurones. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 546–8 Kombian SB, Colmers WE Neuropeptide Y selectively inhibits slow synaptic potentials in rat dorsal raphe nucleus in vitro by a presynaptic action. J Neurosci 1992; 12: 1086–93 Colmers WF, Klapstein GJ, Fourmier A, et al. Presynaptic inhibition by neuropeptide Y in rat hippocampal slice in vitro is mediated by Y2 receptor. Br J Pharmacol 1991; 102: 41–4 Roman FJ, Pascaud X, Duffy O, et al. N-Methyl-D-aspartate receptor complex modulation by neuropeptide Y and peptide YY in rat hippocampus in vitro. Neurosci Lett 1991; 122: 202–4 Colmers WF. Modulation of synaptic tranmission in hippocampus by neuropeptide Y: presynaptic actions. Ann NY Acad Sci 1990; 611: 206–18 Monnet FP, Fournier A, Debonnel G, et al. Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus: I. Involvement of an atypical neuropeptide Y receptor. J Pharmacol Exp Ther 1992; 263: 1212–8 Monnet FP, Debonnel G, Fournier A, et al. Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus: II. Involvement of a subtype of sigma receptor. J Pharmacol Exp Ther 1992; 263: 1219–25 Monnet FP, Debonnel G, Bergeron R, et al. The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussis toxin. Br J Pharmacol 1994; 112: 709–15 Potter EK, Mitchell L, McCloskey MJD, et al. Pre- and postjunctional actions of neuropeptide Y and related peptides. Regul Pept 1989; 25: 167–77 Grundemar L, Grundstrom N, Johansson IGM, et al. Suppression by neuropeptide Y of capsaicin-sensitive sensory nerve-mediated contraction in guinea-pig airways. Br J Pharmacol 1990; 99: 473–6 Grundemar L, Wahlestedt C, Wang ZY. Neuropeptide Y suppresses the neurogenic inflammatory response in the rabbit eye; mode of action. Regul Pept 1993; 43: 57–64 Bendotti C, Vezzani A, Tarizzo G, et al. Increased expression of GAP-43, somatostatin and neuropeptide Y mRNA in the hippocampus during the development of hippocampal kindling in rats. Eur J Neurosci 1993; 5: 1312–20 Rizzi M, Monno A, Samanin R, et al. Electrical kindling of the hippocampus is associated with functional activation of neuropeptide Y-containing neurons. Eur J Neurosci 1993; 5: 1534–8 Fukui K, Kawashima Y, Iizumi H, et al. Immunohistochemical alterations in neuropeptide Y—positive nerve elements in rat cerebral cortex following acute phencyclidine treatment. Neuroreport 1995; 6: 626–8 Nawa H, Bessho Y, Carnahan J, et al. Regulation of neuropeptide expression in cultured cerebral cortical neurons by brain-derived neurotrophic factor. J Neurochem 1993; 60: 772–5 Nawa H, Carnahan J, Call C. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. Eur J Neurosci 1995; 7: 1527–35 Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243–56 Croll SD, Wiegand SJ, Anderson KD, et al. Regulation of neuropeptides in adult rat forebrain by the neurotrophins BDNF and NGF. Eur J Neurosci 1994; 6: 1343–53 Lapchak PA, Araujo DM. Effects of chronic intraventricular nerve growth factor treatment on vasoactive intestinal peptide and neuropeptide Y levels in the hippocampal formation and cerebral cortex following fimbrial transections. Brain Res 1994; 654: 1–7 Jones KR, Farinas I, Backus C, et al. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell 1994; 76: 989–99 Zhou XF, Rush RA. Sympathetic neurons in neonatal rats require endogenous neurotrophin-3 for survival. J Neurosci 1995; 15: 6521–30 Nawa H, Pelleymounter MA, Carnahan J. Intraventricular administration of BDNF increases neuropeptide expression in newborn rat brain. J Neurosci 1994; 14: 3751–65 Verge VMK, Richardson PM, WiesenfeldHallin Z, et al. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci 1995; 15: 2081–96 Allen JM, Tischler AS, Lee YC, et al. Neuropeptide Y (NPY) in PC 12 phaeochromocytoma cultures: responses to dexa-methasone and nerve growth factor. Neurosci Lett 1984; 46: 291–6 Sabol SL, Higuchi H. Transcriptional regulation of the neuropeptide Y gene by nerve growth factor: antagonism by adenosine 3’,5’-monophosphate and phorbol ester. Mol Endocrinol 1990; 4: 384–92 Milner P, Crowe R, Fernyhough P, et al. Nerve growth factor treatment of adult rats selectively enhances innervation of urinogenital tract rather than vascular smooth muscle. Int J Dev Neurosci 1995; 13: 393–401 Oswald RJ, Byers MR. The injury response of pulpal NPY-IR sympathetic fibers differs from that of sensory afferent fibers. Neurosci Lett 1993; 164: 190–4 Tuttle JB, Steers WD. Nerve growth factor responsiveness of cultured major pelvic ganglion neurons from the adult rat. Brain Res 1992; 588: 29–40 Rao MS, Tyrrell S, Landis SC, et al. Effects of ciliary neurotrphic factor (CNTF) and depolarization on neuropeptide expression in cultured sympathetic neurons. Dev Biol 1992; 150: 281–93 Friedman B, Scherer SS, Rudge JS, et al. Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron 1992; 9: 295–305 Barnea A, Cho G, Lu G. Role for glial cells in regulating the functional expression of neuropeptide Y (NPY) neurons in aggregate cultures derived from dissociated fetal brain cells. J Neurosci Res 1994; 38: 459–67 Lerchen RA, Yum DY, Krajcik R, et al. Transcriptional vs posttranscriptional control of neuropeptide Y gene expression. Endocrinology 1995; 136: 833–41 Li JY, Hou XE, Dahlstrom A. GAP-43 and its relation to autonomic and sensory neurons in sciatic nerve and gastrocnemius muscle in the rat. J Auton Nerv Syst 1995; 50: 299–309 Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996 May 30; 381: 415–8 Shigeri Y, Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 1993; 149: 19–22 Garcia De Yebenes E, Li S, Fournier A, et al. Regulation of proopiomelanocortin gene expression by neuropeptide Y in the rat arcuate nucleus. Brain Res 1995; 674: 112–6 Wallengren J, Ekman R, Sundler F. Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venereol 1987; 67: 185–92 Lincoln J, Milner P, Appenzeller O, et al. Innervation of normal human sural and optic nerves by noradrenaline- and peptide-containing nervi vasorum and nervorum: effect of diabetes and alcoholism. Brain Res 1993; 632: 48–56 Unsicker K, Stogbauer F. Screening of adrenal medullary neuropeptides for putative neurotrophic effects. Int J Dev Neurosci 1992; 10: 171–9 White DM. Neuropeptide Y and vasoactive intestinal peptide act indirectly to enhance neurite outgrowth of cultured rat sensory neurons [abstract]. 11th World Congress of An-aesthesiologists; 1996 Apr 14-20; Sydney, 313 Spitsbergen JM, Stewart JS, Tuttle JB. Altered regulation of nerve growth factor secretion by cultured VSMCs from hypertensive rats. Am J Physiol Heart Circ Physiol 1995; 269: H621–8 Hua XY, Boublik JH, Spicer MA, et al. The antinociceptive effect of spinally administered neuropeptide Y: systemic studies on structure-activity relationships. J Pharmacol Exp Ther 1991; 258: 243–8 Mellado M, Gilbert-Rahola J, Lagares R, et al. Dual actions of NPY on nociception in mice. In: Allen J, Cox HM, editors. Neuropeptide Y. Cambridge, England, 1993: A21 De KY, Henry JL. Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. Proc Natl Acad Sci USA 1991; 88: 11344–8 Zhang X, WiesenfeldHallin Z, Hokfelt T. Effect of peripheral axotomy on expression of neuropeptide Y receptor mRNA in rat lumbar dorsal root ganglia. Eur J Neurosci 1994; 6: 43–57 Ewald DA, Sternweis PC, Miller RJ. Guanine nucleotide-binding protein G(o)-induced coupling of neuropeptide Y receptors to Ca2+ channels in sensory neurons. Proc Natl Acad Sci USA 1988; 85: 3633–7 Duggan AW, Hope PJ, Lang CW. Microinjection of neuropeptide Y into the superficial dorsal horn reduces stimulus evoked release of immunoreactive substance P in the anaesthetized cat. Neuroscience 1991; 44: 733–40 Pich EM, Solfrini V, Marrama P, et al. Centrally administered neuropeptide Y fails to increase food intake but enhances hypoalgesia in spontaneously hypertensive rats. Neurosci Lett 1993; 149: 209–12 Fuxe K, Agnati LF, Harfstrand A, et al. On the role of neuropeptide Y in information handeling in the central nervous system in normal and physiopathalogical states. Ann NY Acad Sci 1990; 579: 28–67 Liu H, Brown JL, Jasmin L, et al. Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neu-ropeptides and their receptors. Proc Natl Acad Sei USA 1994; 91: 1009–13 Zhang X, Meister B, Elde R, et al. Large calibre primary afferent neurons projecting to the gracile nucleus express neuropeptide Y: an immunohistochemical and in situ hybridisation study in rats. Eur J Neurosci 1993; 5: 1510–9 Wakisaka S, Kajander KC, Bennett GJ. Increased neuropeptide Y (NPY)-like immunoreactivity in rat sensory neurons following peripheral axotomy. Neurosci Lett 1991; 124: 200–3 Frisen J, Risling M, Theodorsson E, et al. NPY-like immunore-activity in sensory nerve fibers in rat sciatic neuroma. Brain Res 1992; 577: 142–6 Noguchi K, De Leon M, Nahin RL, et al. Quantification of axotomy-induced alteration of neuropeptide mRNAs in dorsal root ganglion neurons with special reference to neuropeptide Y mRNA and the effects of neonatal capsaicin treatment. J Neurosci Res 1993; 35: 54–66 Roberts W. A hypothesis on the physiological basis of causalgia and related pains. Pain 1986; 24: 297–311 Woolf CJ, Doubell TP The pathophysiology of chronic pain-increased sensitivity to low threshold Aβ-fibre inputs. Curr Opin Neurobiol 1994; 4: 525–34 Toth P, Bindokas V, Bleakman D, et al. Mechanism of pre-synaptic inhibitionby neuropeptide Y at sympathetic nerve terminals. Nature 1993; 364: 635–8 McLachlan EM, Janig W, Devor M, et al. Pheripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363: 543–5 Munglani R, Bond A, Smith G, et al. Changes in neuronal mark-ers in a mononeuropathic rat model: relationship between neuropeptide Y, pre-emptive drug treatment and long term mechanical hyperalgesia. Pain 1995; 63: 21–31 Munglani R, Harrison S, Smith G, et al. Persistent changes in neuronal markers in a mononeuropathic rat model despite res-olution of mechanical hyperalgesia [abstract]. Brain Res Assoc 1995; 12: 76 Bennett GJ, Xie Y-K. A peripheral neuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87–108 Munglani R, Harrison S, Smith G, et al. Effect of different pre-emptive treatments on long-term neuropeptide expression in the dorsal root ganglia in a model of neuropathic pain. Br J Anaesth 1995; 74: 482P Jenkins R, Hunt SP. Long-term increase in the levels of c-jun mRNA and Jun protein—like immunoreactivity in motor and sensory neurons following axon damage. Neurosci Lett 1991; 129: 107–10 Jenkins R, McMahon SB, Bond AB, et al. Expression of c-Jun as a response to dorsal root and peripheral nerve section in damaged and adjacent intact primary sensory neurons in the rat. Eur J Neurosci 1993; 5: 751–9 Wakisaka S, Sasaki Y, Kurisu K. Temporal analysis of neu-ropeptide Y expression in the rat trigeminal ganglion following peripheral axotomy of the inferior alveolar nerve. Neurosci Lett 1995; 188: 49–52 Munglani R, Christadoulou E, Fleming B, et al. Peripheral neuropathy causes the expression of NPY in a population of neuronal cell bodies distinct from diaphorase postive neuronal cell bodies in the dorsal root ganglia [abstract]. Brain Res Assoc 1995; 12: 75 Morris R, Southam E, Braid DJ, et al. Nitric oxide may act as a messenger between dorsal root ganglion neurones and their satellite cells. Neurosci Lett 1992; 137: 29–32 Verge VMK, Xu Z, Xu X, et al. Marked increases in nitric oxide synthase mRNA in rat dorsal root ganglia after peripheral axotomy: In situ hybridisation and functional studies. Proc Natl Acad USA 1992; 89: 11617–21 Kowall NW, Ferrante RJ, Beal MF, et al. Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. Neuro-science 1987; 20: 817–28 Munglani R, Hunt S. Molecular biology of pain. Br J Anaesth 1995; 75: 186–92 Millan MJ. Multiple opioid systems and chronic pain. In: Herz A, Akil H, Simon EJ, editors. Opioids II. Berlin: Springer-Verlag, 1993: 127–62 Wakisaka S, Kajander KC, Bennett CJ. Effects of pheripheral nerve injuries and tissue inflammation on the levels of neu-ropeptide Y-like immunoreactivity in rat primary affent neu-rons. Brain Res 1992; 598: 349–52 Ji RR, Zhang X, Wiesenfeld Hallin Z, et al. Expression of neu-ropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J Neurosci 1994; 14: 6423–34 Zhang X, Wiesenfeld-Hallin Z, Hokfelt T. Effects of peripheral axotomy on expression of neuropeptide Y receptor mRNA in rat lumbar dorsal root ganglia. Eur J Neurosci 1994; 6: 43–57 Levine J, Fields H, Basbaum A. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13: 2273–86 Sato J, Perl ER. Adrenergic excitation of cutaneous pain recep-tors induced by peripheral nerve injury. Science 1991; 251: 1608–10 Devor M, Janig W. Activation of myelinated afferents ending in a neuroma by stimulation of the sympathetic supply in a rat. Neurosci Lett 1981; 24: 43–7 Edvinsson L, Ekblad E, Hakanson R, et al. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rab-bit blood vessels. Br J Pharmacol 1984; 83: 519–25 Tracey DJ, Romm MA, Yao NNL. Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y. Brain Res 1995; 669: 245–54 Claxson A, Morris C, Blake D, et al. The anti-inflammatory effects of D-myo-inositol 1,2,6-trisphosphate (PP56) on animal models of inflammation. Agents Actions 1990; 29: 68–70 Feth F, Erdbrugger W, Rascher W, et al. Is PP56 (D-myo-inositol- 1,2,6-triphosphate) an antagonist at neuropeptide Y receptors? Life Sci 1993; 52: 1835–44 Lindh B, Hokfelt T, Elfvin LG, et al. Topography of NPY-, somatostatin-, and VIP-immunoreactive, neuronal sub-populations in the guinea pig celiac-superior mesenteric ganglion and their projection to the pylorus. J Neurosci 1986; 6: 2371–83 Basbaum AI, Fields HL. Endogenous pain control systems: brain stem spinal pathways and endorphin circuitry. Ann Rev Neurosci 1984; 7: 309–88 Doyle CA, Maxwell DJ. Catecholaminaergic innervation of the spinal dorsal horn: a correlated light and electron microscopic analysis of tyrosine hydroxylase-immunoreactive fibres in the cat. Neuroscience 1991; 45: 161–76 Anand P. Nerve growth factor regulates nociception in human health and disease. Br J Anaesth 1995; 75: 201–8 Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353–9 Andreev NY, Dimitrieva N, Koltzenburg M, et al. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympa-thetic post-ganglionic neurones. Pain 1995; 63: 109–15 Tracey DJ, Romm MA, Yao NNL. Peripheral hyperalgesia in experimental neuropathy: excerbation by neuroeptide Y. Brain Res 1995; 669: 245–54 Levine JD, Taiwo YO, Collins SD, et al. Noradrenaline hyper-algesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature 1986; 323: 158–60 Vanos DN, Ramamurthy S, Hoffman J. Intravenous regional block using Ketorolac: preliminary results in the treatment of reflex sympathetic dystrophy. Anaesth Analg 1992; 74: 139–41 Larsson J, Ekblom A, Henriksson K, et al. Concentration of substance P, neurokinin A, calcitonin gene related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991; 20: 326–35 Kozin F, McCarty D, Sims J, et al. The reflex sympathetic dystrophy syndrome. Am J Med 1976; 60: 321–31 Stanley BG, Leibowitz SF. Neuropeptide Y: sof feeding and drinking by injection into the paraventricular nucleus. Life Sci 1984; 35: 2635–42 Akabayashi A, Wahlestedt C, Alexander JT, et al. Specific in-hibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding be-havior and insulin secretion. Mol Brain Res 1994; 21: 55–61 Minami S, Kamagai J, Sugihara H, et al. Central glucodeprivation evoked by the administration of 2-deoxy-D-glucose induces expression of the c-fos gene in a sub population of neuropeptide Y neurones in the rat hypothalamus. Mol Brain Res 1995; 33: 305–10 Rogers P, McKibbin PE, Williams G. Acute fenfluramine ad-ministration reduces neuropeptide Y concentrations in specific hypothalamic regions of the rat: possible implications for the anorectic effect of fenfluramine. Peptides 1991; 12: 251–5 Kaye WH, Berrettini WH, Gwirtsman HE, et al. Altered cere-brospinal fluid neuropeptide Y and peptide YY immunoreactvity in anorexia and bulimia nervosa. Arch Gen Psychiatry 1990; 47: 548–56 McCarthy HD, Kilpatrick AP, Trayhurn P, et al. Widespread increases in regional hypothalamic neuropeptide Y levels in acute cold exposed rats. Neuroscience 1993; 54: 127–32 Saladin R, De Yos P, Guenue Millo M, et al. Transient increase in obese gene expression after food intake or insulin admin-istration. Nature 1995; 377: 527–9 Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530–2 Clark JT, Sahu A, Mrotek JJ, et al. Sexual function and neu-ropeptide Y levels in selected brain regions in male spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 1991; 261: R1234–41 Poggioli R, Vergoni AV, Marrama D, et al. NPY-induced inhibition of male copulatory activity is a direct behavioural effect. Neuropeptides 1990; 16: 169–72 Clark JT. Benextramine, a putative neuropeptide Y receptor an-tagonist, attenuates the termination of receptivity. Physiol Behav 1992; 52: 965–9 Heilig M, Koob GF, Ekman R, et al. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 1994; 17: 80–5 Wahlestedt C, Pich EM, Koob GF, et al. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxy-nucleotides. Science 1993; 259: 528–31 Widerlov E, Lindstrom LH, Wahlestedt C, et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988; 22: 69–79 Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. J Neurochem 1992; 59: 73–80 Wahlestedt C, Karoum F, Jaskiw G, et al. Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on me-dial prefrontal cortex. Proc Natl Acad Sci USA 1991; 88: 2078–82 Kataoka Y, Sakurai Y, Mine K, et al. The involvement of neu-ropeptide Y in the antimuricide action of noradrenaline in-jected into the medial amygdala of olfactory bulbectomized rats. Pharmacol Biochem Behav 1987; 28: 101–3 Frederiksen SO, Ekman R, Gottfries CG, et al. Reduced con-centrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypo-thalamus of brains from schizophrenics. Acta Psychiatr Scand 1991; 83: 273–7 Sakai K, Maedea K, Chiara K, et al. Increases in cortical neu-ropeptide Y and somatostatin concentrations following halo-peridol depot treatment in rats. Neuropeptides 1995; 29: 157–61 Flood JF, Hernandez EN, Morley JE. Modulation of memoryprocessing by neuropeptide Y. Brain Res 1987; 421: 280–90 Flood JF, Baker ML, Hernandez EN, et al. Modulation of mem-ory by neuropeptide Y varies with brain injection site. Brain Res 1989; 503: 73–82 Morley JE, Flood JF. Neuropeptide Y and memory processing. Ann NY Acad Sci 1990; 611: 226–31 Beal MF, Mazurek MF, Chattha GK, et al. Neuropeptide Y immunoreactvity is reduced in cerebral cortex in Alzheimers’s disease. Ann Neurol 1985; 20: 282–8 Allen JM, Ferrier IN, Roberts GW, et al. Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer’s type dementia. J Neurol Sci 1984; 64: 325–31 Gabriel S, Bierer L, Harotunin V, et al. Widespread deficits in somatostatin but not NPY concentrations in Alzheimers’s disease cerebral cortex. Neurosci Lett 1993; 155: 116–20 Phillips HS, Hains JM, Armanini M, et al. BDNF mRNA is decreased in the hippocampus of individuals with Al-zheimers’s disease. Neuron 1991; 7: 695–702 Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens 1995; 13: 385–95 Shine J, Potter EK, Biden T, et al. Neuropeptide Y and regulation of the cardivascular system. J Hypertens 1994; 12: S41–5 Wahlestedt C, Yanaihara N, Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and re-lated peptides. Regul Pept 1986; 13: 307–18 Grundemar L, Jonas SE, Morner N, et al. Characterization of vascular neuropeptide Y receptors. Br J Pharmacol 1992; 105: 45–50 Modin A, Pernow J, Lundberg JM. Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur J Pharmacol 1991; 203: 165–71 Tessel RE, Miller DW, Misse GA, et al. Characterization of vascular postsynaptic NPY receptor function and regulation and differential sensitivity of Y1 and Y2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides 1993; 25: 289–98 Benarroch EE, Schmelzer JD, Ward KK, et al. Noradrenergic and neuropeptide Y mechanisms in guanethidine-sympathectomized rats. Am J Physiol Regul Integr Comp Physiol 1990; 259: R371–5 Grundemar L, Hakanson R. Multiple neuropeptide Y receptors are involved in cardiovascular regulation: peripheral and central mechanisms. Gen Pharmacol 1993; 24: 785–96 Han C, Abel PW. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol 1987; 9: 675–81 Macrae IM, Dewar D, Reid JL, et al. Specific alterations in cardiovascular function and in glucose utilisation within lower brainstem nuclei following intracisternal neuropeptide Y in the conscious rat. Brain Res 1990; 515: 99–103 Grundemar L, Wahlestedt C, Reis DJ. Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. Neurosci Lett 1991; 122: 135–9 Shih CD, Chan JYH, Chan SHH. Tonic suppression of baroreceptor reflex response by endogenous neuropeptide Y at the nucleus tractus solitarius of the rat. Neurosci Lett 1992; 148: 169–72 McAuley MA, Macrae IM, Reid JL. The cardiovascular actions of clonidine and neuropeptide-Y in the ventrolateral medulla of the rat. Br J Pharmacol 1989; 97: 1067–74 Yang SN, Narvaez JA, Bjelke B, et al. Microinjections of sub-picomolar amounts of NPY(13–36) into the nucleus tractus solitarius of the rat counteract the vasodepressor responses of NPY(1–36) and of a NPY Y1 receptor agonist. Brain Res 1993; 621: 126–32 Yang SN, Fior DR, Hedlund PB, et al. Selective modulation of the NPY receptors of the Y2 subtype by alpha2 receptors in the nucleus tractus solitarii of the rat: a cardiovascular and quantitative receptor autoradiographical analysis. Brain Res 1994; 654: 137–44 Yang SN, Fior DR, Hedlund PB, et al. Coinjections of NPY(1–36) or (Leu31, Pro34)NPY with adrenaline in the nucleus tractus solitarius of the rat counteract the vasodepressor responses to adrenaline. Neurosci Lett 1994; 171: 27–31 Yang SN, Bjelke B, Narvaez JA, et al. Counteraction of NPY-induced c-Fos expression in the nucleus tractus solitarii by alpha2 receptor agonists. Neuroreport 1995; 6: 384–8 Maisel AS, Scott NA, Motulsky HJ, et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 1989; 86: 43–8 Ullman B, Franco Cereceda A, Hulting J, et al. Elevation of plasma neuropeptide Y—like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med 1990; 228: 583–9 Solt V, Brown M, Kennedy B, et al. Elevated insulin, norepi-nephrine and neuropetide Y in hypertension. Am J Hypertens 1990; 3: 823–8 Lettgen B, Wagner S, Hanze J, et al. Elevated plasma concentration of neuropeptide Y in adolescents with primary hyper-tension. J Hum Hypertens 1994; 8: 345–9 Wocial B, Ignatowska Switalska H, Pruszczyk P, et al. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 1995; 4: 143–7 Lundberg JM, Hemsen A, Fried G, et al. Co-release of neuropeptide Y (NPY)—like immunoreactivity and catechola-mines in newborn infants. Acta Physiol Scand 1986; 126: 471–3 Lundberg JM, Rudehill A, Sollevi A, et al. Frequency- and reserpine-dependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett 1986; 63: 96–100 Lemne CE, Lundeberg T, Theodorsson E, et al. Increased basal concentrations of plasma endothelin in borderline hypertension. J Hypertens 1994; 12: 1069–74 Tseng A, Inglis A, Selbie LA, et al. Neuropeptide Y analog with selective antagonism of effects mediated by post junctional Yi receptors. Eur J Pharmacol 1994; 271: 265–71 Rudehill A, Sollevi A, Franco Cereceda A, et al. neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides 1986; 7: 821–6 Michel MC, Wirth SC, Zerkowski HR, et al. Lack of inotropic effects of neuropeptide Y in human myocardium. J Cardiovasc Pharmacol 1989; 14: 919–22 Hulting J, Sollevi A, Ullman B, et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 1990; 24: 102–8 Ullman B, Jensen-Urstad M, Hulting J, et al. Neuropeptide Y, noradrenaline and invasive haemodynamic data in mild to moderate chronic congestive heart failure. Clin Physiol 1993; 13: 409–18 Omland T, Opstad PK, Dickstein K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am Heart J 1994; 127: 774–9 Feng QP, Hedner T, Andersson B, et al. Cardiac neuropetide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994; 71: 261–7 Kahan T, Taddei S, Pedrinelli R, et al. Nonadrenergic sympathetic vascular control of the human forearm in hypertension: possible involvement of neuropeptide Y. J Cardiovasc Pharmacol 1992; 19: 587–92 Fuhlendorff J, Gether U, Aakerlund L, et al. (Leu31, Pro34) Neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci USA 1990; 87: 182–6 Dhanoa DS. Neuropeptide Y: a promising therapeutic target. Exp Opin Ther Patents 1995; 5: 391–6 Rudolf K, Ebelein W, Engel W, et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP 3226. Eur J Pharmacol 1994; 271: R11–3 Serradeille Gal C, Valette G, Rouby PE, et al. SR120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett 1995; 362: 192–6 Leban JJ, Heyer D, Landavazo A, et al. Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor. J Med Chem 1995; 38: 1150–7 Grouzmann E, Cressier F, Walker P, et al. Interactions between NPY and its receptor: assessment using anti-NPY antibodies. Regul Pept 1994; 54: 439–44 Laduron PM. Towards genomic pharmacology: from membranal to nuclear receptors. Adv Drug Res 1992; 22: 107–48 Cox HM, Cuthbert AW. The effects of neuropeptide Y and its fragments upon basal and electrically stimulated ion secretion in rat jejunum mucosa. Br J Pharmacol 1990; 101: 247–52 Cox HM, Krstenansky JL. The effects of selective amino acid substitution upon neuropeptide Y antisecretory potency in rat jejunum mucosa. Peptides 1991; 12: 323–7 Cox HM, Cuthbert AW, Hakanson R, et al. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia. J Physiol 1988; 398: 65–80 Higuchi H, Costa E, Yang H-YT. Neuropeptide Y inhibits the nicotine-mediated release of catecholamines from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1988; 244: 468–74 Schwartz TW, Fuhlendorff J, Kjems LL, et al. Signal epitopes in the three dimensional structure of neuropeptide Y. Ann NY Acad Sci 1990; 611: 35–47